CME Accreditation & Digital Educational Modules

CME Accreditation for Gaucher Disease

Activity Description

Drs. Ozlem Goker-Alpan, Gregory Grabowski and Soumeya Bekri provide a thorough description of the clinical diversity and genetic variations that can help guide personalized therapies. The session includes a Q&A section at the end hosted by Dr. Uma Ramaswami.

Clinical Diversity and Genetic Variation in Lysosomal Disorders

Start date: July 16, 2021
End date: July 15, 2022
Estimated time to complete: 2 hours

Activity Faculty

Ozlem Goker-Alpan, MD
Founder and President
Lysosomal & Rare Disorders Research & Treatment Center (LDRTC)

Gregory Grabowski, MD
Department of Pediatrics
University of Cincinnati College of Medicine
Division of Human Genetics

Soumeya Bekri, MD, PhD
Rouen University Hospital, France

Target Audience

This activity provides continuing education credit for Physicians, Physician Assistants, Nurses, Nurse Practitioners, Genetic Counselors as well as a statement of participation for other attendees.

Learning Objectives

At the end of this activity, participants should be able to:

  • Explain the principles of Pathogenic Processes in LSDs.
  • Explain that lysosomal composition, shape, contents, numbers differ between cell types
    and have an effect on disease expression.
  • Review the evolving understanding of lysosomal autophagy functions.

AffinityCE designates this enduring activity for a maximum of 2 AMA PRA Category 1 Credits™ for Physicians, PA’s, NP’s and Genetic Counsleors. This activity provides a maximum of 2 hours of continuing nursing education credit. All other health care professionals completing this continuing education activity will be issued a Statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

Activity Description

Drs. Shoshana Revel-Vilk and Neil Weinreb discuss the latest digital and pharmaceutical advances that are advancing how we manage persons with lysosomal storage disorders, including Gaucher disease. The session includes a Q&A section at the end hosted by Dr. Ozlem Goker-Alpan.

Novel Technologies and Emerging Therapies for Precision Medicine

Start date: July 16, 2021
End date: July 15, 2022
Estimated time to complete: 1.5 hours

Activity Faculty

Shoshana Revel-Vilk, MD, PhD
Shaare Zedek Medical Center, Israel

Neil Joseph Weinreb, MD
University of Miami, FL, USA

Learning Objectives

At the end of this activity, participants should be able to:

  • Detail the different technologies used in digital health.
  • Discuss the benefits and challenges of the different technologies of digital health.
  • Explain projects of digital health in Gaucher disease.
  • Identify some of the different clinical manifestations of representative lysosomal
    storage disorders (LSDs) and how persistent unmet needs for treatment are driving the
    search for innovative small molecule treatments.
  • Identify the increasing numbers of non-chaperone small molecule oral therapies as
    alternative treatments for disorders currently treated with intravenous ERTs and as novel treatments for diseases in which ERT is either insufficient or inapplicable.

AffinityCE designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™ for Physicians, PA’s, NP’s and Genetic Counsleors. This activity provides a maximum of 1.5 hours of continuing nursing education credit. All other health care professionals completing this continuing education activity will be issued a Statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

Activity Description

At the American Society of Hematology Annual Meeting (ASH 2020), new information and data were presented on Gaucher disease, a rare lysosomal storage disorder, that requires a team of health care professionals to properly manage. This CME activity highlights the latest information about Gaucher disease from ASH 2020 and provides expert analysis of its clinical relevance for busy members of the care team in order to help them care for patients with this rare condition.

Gaucher Disease Research Highlights: ASH 2020

Start date: March 31, 2021
End date: March 31, 2022
Estimated time to complete: 0.25 hours

Activity Faculty

Derralynn Hughes, MD, DPhil, FDCP, FRCPath
Professor of Experimental Haematology
University College London
Clinical Director of Research and Innovation
Royal Free London NHS Foundation Trust
United Kingdom

Target Audience

This activity has been designed to meet the educational needs of physicians caring for individuals with Gaucher disease. Other members of the care team may also participate.

Learning Objectives

After participating in the activity, learners should be better able to:

  • Describe the latest research being presented to better manage people with Gaucher disease and its clinical relevance.

American Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™.

Additional Educational Modules

CME IS NO LONGER AVAILABLE FOR THESE MODULES:

Activity Description

At WORLDSymposium 2020, new information and data were presented on Gaucher disease, a rare lysosomal storage disorder. This CME/CNE activity highlights the latest information about Gaucher disease from WORLDSymposium and provides expert analysis of its clinical relevance for busy members of the care team in order to help them care for patients with this rare disease.

Gaucher Disease Research Highlights

Release date: 04/30/20
Expiration date: 04/30/21
Estimated time to complete: 0.25 hours

Activity Faculty

Neal Weinreb, MD, FACP
Regional Coordinator and Chair of the International Collaborative Gaucher Group
University of Miami UHealth Sylvester Cancer Center Coral Springs
Coral Springs, FL

Target Audience

This activity has been designed to meet the educational needs of physicians, nursing professionals and other members of the team caring for patients with Gaucher disease.

Learning Objective

After participating in the activity, learners should be better able to:

  • Describe the latest research being presented to better manage Gaucher disease and its clinical relevance

Activity Description

Although making a proper diagnosis can sometimes be a challenge even for common illnesses, in cases of patients who present with a rare disease such as Gaucher disease, properly diagnosing the disorder is especially challenging. Gaucher disease specialists often come across individuals who have lived with symptomatic Gaucher disease for years—into middle age or beyond—at which point treatment is much less effective. Although these individuals can gain some benefit from treatment, irreversible damage has often already occurred. Early consideration of Gaucher disease in the differential diagnosis of non-Gaucher disease specialists could allow individuals to avoid this outcome and gain maximal quality of life with effective therapy.

The modules of the digital curriculum below focus on the challenges of making a diagnosis of Gaucher disease, and how to co-manage these patients with the Gaucher disease expert once diagnosed.

Modules include:

The activities in this curriculum were approved for AMA PRA Category 1 Credit™. 

Release date: 02/28/19
Expiration date: 02/28/20
Estimated time to complete: 0.25 hours

Activity Faculty

Neal Weinreb, MD, FACP
Regional Coordinator and Chair of the International Collaborative Gaucher Group
University of Miami UHealth Sylvester Cancer Center Coral Springs
Coral Springs, FL

Living a Better Today

Skip to content